Duavee and Nicotine: The Interaction Every Menopausal Woman Should Understand Before She Lights Up or Reaches for a Patch

Why This Interaction Exists: Nicotine, Enzymes, and Estrogen Metabolism

Duavee pairs conjugated estrogens (CE) at 0.45 mg with bazedoxifene (BZA) at 20 mg. The estrogen component handles vasomotor symptom relief. Bazedoxifene acts as a selective estrogen receptor modulator (SERM) to protect the uterine lining, replacing the progestogen that would otherwise be needed in women who still have a uterus. The FDA prescribing information for Duavee describes this combination as a "tissue-selective estrogen complex" or TSEC.

The interaction with nicotine operates on two levels: enzyme induction and direct vascular toxicity.

How Nicotine Induces CYP1A2

Cigarette smoke, specifically its polycyclic aromatic hydrocarbon (PAH) constituents rather than nicotine alone, strongly induces the hepatic enzyme CYP1A2. Research published on PubMed documents that CYP1A2 induction by smoking accelerates estrogen 2-hydroxylation, shifting estrogen metabolism toward catechol estrogens and reducing circulating levels of bioactive estrogen. For women using oral or transmucosal estrogen-containing therapies, this means lower peak plasma concentrations and a shorter half-life for the estrogenic fraction.

Nicotine itself also activates CYP2B6 and to a lesser extent CYP2A6, the primary enzyme responsible for cotinine formation. While bazedoxifene is metabolized predominantly via UGT1A conjugation rather than CYP pathways, the estrogen component of Duavee is squarely in the CYP1A2 firing line. Women who smoke a pack a day may achieve meaningfully lower CE exposure than non-smokers taking the same 0.45 mg tablet.

Direct Vascular Toxicity: A Second, Independent Pathway

Beyond enzyme kinetics, nicotine exerts direct endothelial injury. It raises circulating fibrinogen, promotes platelet aggregation, and increases thromboxane A2 relative to prostacyclin. A landmark analysis in Circulation established that smoking potentiates coagulation activation in a dose-dependent manner. Estrogen already shifts the hemostatic balance slightly toward coagulation by raising factor VII and reducing antithrombin III. Combine estrogen's procoagulant effect with nicotine's platelet-activating and fibrinogen-raising effects and the resulting thrombotic risk is not merely additive.

Women over 60 who smoke and use oral estrogen-based therapies carry a substantially elevated risk of myocardial infarction and ischemic stroke compared with non-smokers on the same therapy. The Women's Health Initiative (WHI) estrogen-plus-progestin trial, though it studied a different formulation than Duavee, provided the foundational cardiovascular safety dataset for menopausal estrogen therapy and showed that baseline cardiovascular risk factors, including smoking, modify absolute risk considerably.

The FDA Label Warning on Smoking: What It Actually Says

The Duavee prescribing information carries a boxed warning, the FDA's most serious caution, on cardiovascular disorders. The label states explicitly that "estrogens with or without progestins should not be used" in women with known cardiovascular disease risk factors that include tobacco use, and directs that estrogen-containing drugs should not be prescribed to women who smoke, particularly those aged 35 and older.

This is not a theoretical caution.

The same class-wide warning that appears on oral contraceptives, which are contraindicated in smokers over 35, applies conceptually here. The mechanistic basis is shared: estrogen plus tobacco equals a substantially heightened risk of arterial thrombosis, venous thrombosis, and stroke. ACOG Practice Bulletin No. 141 classifies active smoking as a factor that warrants individualized risk assessment before any systemic estrogen therapy is started.

Quantifying the Risk: What the Numbers Show

Exact pharmacokinetic data for CE 0.45 mg/BZA 20 mg in smokers specifically is not available in the published literature. This is a gap worth naming plainly. The SMART trials (Studies of Women's Response to Bazedoxifene/Conjugated Estrogens), the registration program for Duavee comprising five phase 3 trials, enrolled postmenopausal women but did not stratify published efficacy outcomes by smoking status. The absence of that subgroup analysis is not reassurance. It means any clinician prescribing Duavee to a smoker is extrapolating from class-level data and mechanism, not from TSEC-specific trials.

What the class-level data does show:

• Smokers taking oral conjugated estrogens have approximately 30 to 40 percent lower serum estrone sulfate levels than non-smokers on the same dose, consistent with CYP1A2-driven acceleration of metabolism.
• The relative risk of venous thromboembolism (VTE) with combined estrogen therapy and smoking has been estimated at approximately 2.5- to 4-fold compared to estrogen alone in several case-control studies, including data reviewed by the Menopause Society (formerly NAMS) in its 2022 position statement on hormone therapy.
• Transdermal estrogen, which avoids first-pass hepatic metabolism and therefore largely sidesteps CYP1A2 induction, carries a lower VTE signal than oral estrogen in observational studies. A 2011 BMJ case-control study (ESTHER) found that oral but not transdermal estrogen was associated with a statistically significant elevation in VTE risk.

Duavee is an oral preparation. This matters because the first-pass effect means that whatever CYP1A2 induction smoking produces hits the estrogen before it ever reaches systemic circulation.

A practical way to think about this: Duavee in a smoker operates as if the dose is lower than labeled (due to induced metabolism) while the cardiovascular risk is higher than labeled (due to combined vascular toxicity). The woman gets less benefit and more risk. This is the framework WomanRx clinicians use when counseling patients on whether Duavee is appropriate.

Does the Type of Nicotine Delivery Change the Risk?

This question comes up constantly. Women who have switched from cigarettes to nicotine replacement therapy (NRT) or e-cigarettes often assume the interaction is resolved. The answer depends on which part of the interaction you are asking about.

PAH Induction: Mostly a Cigarette Problem

The CYP1A2 induction responsible for accelerated estrogen metabolism is driven primarily by PAHs in combusted tobacco smoke, not by nicotine itself. A woman who has completely switched to nicotine patches, gum, or lozenges should, over several weeks, lose the enzyme-induction component of the interaction as CYP1A2 activity returns toward baseline. PubMed-indexed pharmacology reviews confirm that CYP1A2 induction is reversible upon smoking cessation, with enzyme activity normalizing within approximately 1 to 2 weeks.

E-cigarettes are a partial story. Most e-cigarette aerosols contain nicotine but far fewer PAHs than combusted cigarettes. The CYP1A2 induction is likely lower than with cigarettes, though data from the CDC on e-cigarette aerosol composition confirms that some heating of organic compounds does produce low levels of PAHs. The CYP1A2 induction from vaping is probably less than from cigarettes but has not been measured directly in the context of estrogen pharmacokinetics.

Vascular Toxicity: A Nicotine Problem Regardless of Delivery

The platelet-activating and endothelial-damaging effects of nicotine are present regardless of whether it arrives via cigarette, patch, gum, or vape. Nicotine itself raises heart rate and blood pressure, promotes platelet aggregation, and causes endothelial dysfunction. Women using NRT at therapeutic doses while on Duavee still carry the vascular interaction, even if the metabolic interaction is reduced.

The bottom line: switching from cigarettes to NRT patches or gum resolves roughly half the interaction (the metabolic half) but not the vascular half. Full cessation resolves both.

Duavee and Alcohol: A Separate But Related Question

Women often ask about alcohol because "can I drink on Duavee" appears alongside smoking questions in nearly every patient conversation. The answer is different from the nicotine answer but still warrants care.

Alcohol inhibits CYP enzymes at moderate-to-high doses, which is the opposite of what nicotine does. A moderate amount of alcohol (one to two drinks) may actually raise circulating estrogen levels slightly by slowing hepatic estrogen clearance. A study in the Journal of the National Cancer Institute found that postmenopausal women using hormone therapy who consumed alcohol had higher circulating estradiol than non-drinkers on the same therapy. Higher estrogen exposure may mean more estrogenic side effects (breast tenderness, nausea, fluid retention) for some women.

Heavy alcohol use carries independent cardiovascular and hepatic risk that compounds any estrogen-related risk.

Occasional, moderate alcohol use is not contraindicated with Duavee, but daily or heavy drinking is a reason to reassess the overall risk-benefit calculation with your prescriber.

Life-Stage Considerations: Who Takes Duavee and What Smoking Means at Each Stage

Duavee is approved only for postmenopausal women who have a uterus and who need treatment for moderate to severe vasomotor symptoms. It is not approved for:

• Women in their reproductive years
• Perimenopausal women who are still having menstrual cycles (even irregular ones)
• Women who are pregnant or breastfeeding
• Women who have had a hysterectomy (they can use estrogen alone without a SERM or progestogen)

Within the approved postmenopausal population, smoking creates meaningfully different risk profiles across ages.

Early Postmenopause (Ages 50 to 59 or Within 10 Years of Final Menstrual Period)

The "timing hypothesis" (sometimes called the "window of opportunity") supported by WHI re-analyses and the KEEPS trial holds that estrogen therapy initiated close to menopause carries the most favorable cardiovascular risk profile. A woman in early postmenopause who smokes still carries elevated arterial thrombosis risk, but her absolute baseline cardiovascular risk is lower than an older postmenopausal woman. The benefit-risk calculation may still favor treatment for severe vasomotor symptoms if smoking cessation support is offered simultaneously.

Later Postmenopause (Ages 60 and Older or More Than 10 Years From Final Menstrual Period)

Absolute cardiovascular event rates are substantially higher in this group. The Menopause Society 2022 position statement states that hormone therapy should generally not be initiated more than 10 years after menopause or after age 60 without a careful individual risk assessment. Adding active smoking to that calculus makes Duavee a difficult choice to justify in this age group. Non-hormonal alternatives for vasomotor symptoms (fezolinetant, paroxetine 7.5 mg, gabapentin) should be discussed explicitly.

Pregnancy, Lactation, and Contraception: Required Safety Information

Duavee is contraindicated in pregnancy. If you take Duavee and discover you are pregnant, stop the medication immediately and contact your healthcare provider. While Duavee is approved only for postmenopausal women (and therefore pregnancy is not expected), postmenopausal status must be confirmed before prescribing. Women in perimenopause who retain ovulatory cycles, even infrequently, could theoretically conceive.

What the label says: The Duavee prescribing information states that CE/BZA can cause fetal harm based on the known effects of estrogens on the developing fetus, including urogenital malformations reported with diethylstilbestrol (DES), a related compound. Bazedoxifene, as a SERM, also has potential teratogenicity based on animal data showing embryolethality and fetal abnormalities.

Lactation: Duavee is not indicated in lactating women. Estrogens reduce milk volume by suppressing prolactin. Bazedoxifene transfer into human breast milk has not been studied. Prescribers should not initiate Duavee in a breastfeeding woman.

Contraception: Because Duavee is intended for confirmed postmenopausal women, contraception is not routinely co-prescribed. A woman who is perimenopausal and still at risk of pregnancy must use contraception before starting any estrogen therapy. ACOG recommends that women be confirmed postmenopausal (12 consecutive months without a menstrual period in the absence of other causes) before initiating therapies like Duavee that are not contraception-appropriate.

Who Duavee Is and Is Not Right For, by Life Stage and Condition

Right for (generally)

• Postmenopausal women with an intact uterus experiencing moderate to severe hot flashes
• Women who cannot tolerate progestogen-based regimens due to side effects like mood changes or bleeding
• Women with PCOS who have reached postmenopause and retain their uterus (PCOS does not contraindicate Duavee, though metabolic monitoring remains important)
• Women with osteoporosis risk: Duavee has shown statistically significant preservation of lumbar spine BMD in the SMART-5 trial, a secondary benefit in women at fracture risk

Not right for (generally)

• Women who smoke and are unwilling or unable to quit, given the compounded cardiovascular and thrombotic risk
• Women with a personal history of VTE, stroke, or myocardial infarction (Duavee prescribing information lists these as contraindications)
• Women with known or suspected estrogen-dependent cancers (breast cancer, endometrial cancer)
• Women with active liver disease (impairs estrogen and bazedoxifene metabolism)
• Reproductive-age women, perimenopausal women still cycling, or any woman who could become pregnant
• Women with a history of hereditary angioedema (estrogen can trigger attacks)

Other Drug Interactions Worth Knowing

Nicotine is the focus here, but Duavee has additional interactions a prescriber needs to review.

Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) can reduce both CE and BZA exposure significantly. The Duavee label specifically flags these. Conversely, strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit in large quantities) may raise circulating CE levels.

Cholestyramine and other bile acid sequestrants can impair bazedoxifene absorption if taken simultaneously; spacing by at least 4 hours is recommended.

Women on thyroid hormone replacement should know that oral estrogen increases thyroid-binding globulin (TBG), which can bind more thyroxine and leave less free T4 available. This is a well-documented pharmacodynamic interaction that may require an upward adjustment in levothyroxine dose. Your thyroid levels should be rechecked 6 to 8 weeks after starting Duavee.

Conditions That Change the Risk Equation

Several female-specific conditions alter how you and your prescriber should think about this interaction.

PCOS: Women with PCOS often have insulin resistance and a pre-existing metabolic risk profile. Smoking worsens insulin resistance independently. The combination of PCOS-related cardiovascular risk, nicotine, and oral estrogen may place a woman's absolute risk higher than any single factor suggests.

History of estrogen-sensitive clotting disorders: Factor V Leiden heterozygosity, prothrombin gene mutation, or protein C/S deficiency substantially increase baseline VTE risk. A thrombophilia screen before starting oral estrogen is reasonable in women with personal or strong family history of unprovoked clots, and smoking on top of a thrombophilia is a near-absolute reason to choose non-hormonal therapy.

Endometriosis: Postmenopausal women with a history of endometriosis are sometimes counseled toward estrogen-only therapy to avoid the endometrial proliferation concern. Duavee's BZA component provides uterine protection without progestogen, which makes it pharmacologically interesting in this group. Smoking does not change the endometriosis calculus directly but does change the vascular risk.

Female pattern hair loss and hormonal acne: These are predominantly reproductive-age concerns and do not apply to the postmenopausal Duavee population. However, if a woman asks, BZA has mild anti-estrogenic effects at some tissue sites and is unlikely to worsen androgenic conditions.

Practical Steps if You Smoke and Your Clinician Has Recommended Duavee

1. Talk honestly with your prescriber about your current tobacco or nicotine use before the prescription is written. The risk calculation changes materially depending on whether you smoke 5 cigarettes a day or 25.

2. Request a cardiovascular risk assessment. Blood pressure, fasting lipids, and a personal and family history of VTE or arterial events should all be documented before Duavee is started in anyone with nicotine exposure.

3. Ask about smoking cessation support. Varenicline (Chantix) and bupropion are both evidence-based first-line pharmacotherapies for cessation. A 2016 Cochrane review found varenicline significantly more effective than NRT or bupropion alone. Cessation before starting Duavee is the cleanest solution.

4. If you switch to NRT, tell your prescriber so the CYP1A2 induction risk can be reconsidered at your next review, typically 4 to 8 weeks after the switch, when enzyme activity should have normalized.

5. If vasomotor symptoms remain severe and you are unwilling or unable to stop smoking, ask specifically about non-hormonal options. Fezolinetant (Veozah), approved by the FDA in May 2023 at 45 mg once daily, is a neurokinin 3 receptor antagonist with no estrogenic activity and no known nicotine interaction.

6. If you do start Duavee while working toward cessation, schedule a follow-up in 8 to 12 weeks to assess whether vasomotor symptom relief is adequate. Inadequate relief in a smoker may reflect reduced CE exposure from CYP1A2 induction rather than an inherent lack of response to the drug.